Status:
RECRUITING
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Conditions:
Soft Tissue Sarcomas
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The trial will use neoadjuvant hypofractionated radiotherapy followed by surgical resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over a shorter course (5 or 1...
Detailed Description
Study Objectives: Primary: * To investigate the efficacy of neoadjuvant hypo-fractionated radiotherapy (HRT) followed by surgical resection in the treatment of soft tissue sarcoma (STS) as measured ...
Eligibility Criteria
Inclusion
- Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
- ECOG performance status 0-2
- Patient must be deemed able to comply with radiation treatment and surgery
Exclusion
- History of prior radiation to the same area to be irradiated
- Pregnancy
- Active collagen vascular disease or patients genetically predisposed to increased radiation related side effects
Key Trial Info
Start Date :
March 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04506008
Start Date
March 2 2021
End Date
June 1 2027
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232